These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11052337)

  • 1. Tolcapone-related fulminant hepatitis: electron microscopy shows mitochondrial alterations.
    Spahr L; Rubbia-Brandt L; Burkhard PR; Assal F; Hadengue A
    Dig Dis Sci; 2000 Sep; 45(9):1881-4. PubMed ID: 11052337
    [No Abstract]   [Full Text] [Related]  

  • 2. Tolcapone and fulminant hepatitis.
    Assal F; Spahr L; Hadengue A; Rubbia-Brandt L; Burkhard PR
    Lancet; 1998 Sep; 352(9132):958. PubMed ID: 9752821
    [No Abstract]   [Full Text] [Related]  

  • 3. Catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Henry C; Wilson JA
    Lancet; 1998 Jun; 351(9120):1965-6. PubMed ID: 9654299
    [No Abstract]   [Full Text] [Related]  

  • 4. Update on "open study of the catechol-O-methyltransferase inhibitor tolcapone in major depressive disorder".
    Moroz G; Magni G; Fava M
    J Clin Psychopharmacol; 2000 Apr; 20(2):285. PubMed ID: 10770481
    [No Abstract]   [Full Text] [Related]  

  • 5. Vitiligo associated with tolcapone and levodopa in a patient with Parkinson's disease.
    Sabaté M; Bosch A; Pedrós C; Figueras A
    Ann Pharmacother; 1999 Nov; 33(11):1228-9. PubMed ID: 10573327
    [No Abstract]   [Full Text] [Related]  

  • 6. Tolcapone (Tasmar).
    Robertson S
    CMAJ; 1999 Apr; 160(7):1052, 1056. PubMed ID: 10207353
    [No Abstract]   [Full Text] [Related]  

  • 7. Hepatotoxic profile of catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Benabou R; Waters C
    Expert Opin Drug Saf; 2003 May; 2(3):263-7. PubMed ID: 12904105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolcapone-related liver dysfunction: implications for use in Parkinson's disease therapy.
    Borges N
    Drug Saf; 2003; 26(11):743-7. PubMed ID: 12908845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of tolcapone in the cerebrospinal fluid of parkinsonian subjects.
    Russ H; Müller T; Woitalla D; Rahbar A; Hahn J; Kuhn W
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Dec; 360(6):719-20. PubMed ID: 10619191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Catechol-O-methyltransferase inhibitors in Parkinson's disease.
    Harper J; Vieira B
    Lancet; 1998 Aug; 352(9127):578. PubMed ID: 9716090
    [No Abstract]   [Full Text] [Related]  

  • 11. [Serious tolpcapone-induced hepatitis 17 months after commencing treatment].
    Korri H; Awada A
    Rev Neurol (Paris); 2005 Nov; 161(11):1113-5. PubMed ID: 16288178
    [No Abstract]   [Full Text] [Related]  

  • 12. Neuroleptic malignant-like syndrome in an elderly patient caused by abrupt withdrawal of tolcapone, a-catechol-o-methyl transferase inhibitor.
    Iwuagwu CU; Riley D; Bonoma RA
    Am J Med; 2000 Apr; 108(6):517-8. PubMed ID: 10866587
    [No Abstract]   [Full Text] [Related]  

  • 13. The rise and fall of tolcapone.
    Colosimo C
    J Neurol; 1999 Oct; 246(10):880-2. PubMed ID: 10552233
    [No Abstract]   [Full Text] [Related]  

  • 14. Capture compound mass spectrometry sheds light on the molecular mechanisms of liver toxicity of two Parkinson drugs.
    Fischer JJ; Michaelis S; Schrey AK; Graebner OG; Glinski M; Dreger M; Kroll F; Koester H
    Toxicol Sci; 2010 Jan; 113(1):243-53. PubMed ID: 19783845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients.
    Baas H; Beiske AG; Ghika J; Jackson M; Oertel WH; Poewe W; Ransmayr G
    Neurology; 1998 May; 50(5 Suppl 5):S46-53. PubMed ID: 9591522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolcapone: more than meets the eye?
    Deleu D; Hanssens Y
    Am J Health Syst Pharm; 2000 Aug; 57(16):1534. PubMed ID: 10965399
    [No Abstract]   [Full Text] [Related]  

  • 17. Tolcapone for Parkinson's disease.
    Med Lett Drugs Ther; 1998 Jun; 40(1028):60-1. PubMed ID: 9629124
    [No Abstract]   [Full Text] [Related]  

  • 18. Extending levodopa action: COMT inhibition.
    Martínez-Martín P; O'Brien CF
    Neurology; 1998 Jun; 50(6 Suppl 6):S27-32; discussion S44-8. PubMed ID: 9633684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroleptic malignant-like syndrome and acute hepatitis during tolcapone and clozapine medication.
    Blum MW; Siegel AM; Meier R; Hess K
    Eur Neurol; 2001; 46(3):158-60. PubMed ID: 11598337
    [No Abstract]   [Full Text] [Related]  

  • 20. Tolcapone in stable Parkinson's disease: efficacy and safety of long-term treatment. Tolcapone Stable Study Group.
    Waters CH; Kurth M; Bailey P; Shulman LM; LeWitt P; Dorflinger E; Deptula D; Pedder S
    Neurology; 1998 May; 50(5 Suppl 5):S39-45. PubMed ID: 9591521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.